Connect Biopharma Limite...

0.68
-0.02 (-2.83%)
At close: Apr 23, 2025, 3:59 PM
0.70
3.47%
After-hours: Apr 23, 2025, 07:07 PM EDT
-2.83%
Bid 0.68
Market Cap 37.64M
Revenue (ttm) 24.12M
Net Income (ttm) -21.27M
EPS (ttm) -0.28
PE Ratio (ttm) -2.43
Forward PE -0.29
Analyst Buy
Ask 0.73
Volume 46,622
Avg. Volume (20D) 101,044
Open 0.72
Previous Close 0.70
Day's Range 0.65 - 0.72
52-Week Range 0.51 - 2.08
Beta -0.22

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosin...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 62
Stock Exchange NASDAQ
Ticker Symbol CNTB
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CNTB stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 1076.47% from the latest price.

Stock Forecasts
3 weeks ago
+4.04%
Connect Biopharma shares are trading higher on pos... Unlock content with Pro Subscription